45 results on '"Kristensen, Claus Andrup"'
Search Results
2. High-dose loco-regional pattern of failure after primary radiotherapy in p16 positive and negative head and neck squamous cell carcinoma – A DAHANCA 19 study
3. Tumor volume and cancer stem cell expression as prognostic markers for high-dose loco-regional failure in head and neck squamous cell carcinoma – A DAHANCA 19 study
4. Patient-reported outcome during radiotherapy for head and neck cancer: the use of different PRO questionnaires
5. Recommendations for a Patient Concerns Inventory specific to patients with head and neck cancer receiving palliative treatment
6. FDG-PET/CT identified distant metastases and synchronous cancer in squamous cell carcinoma of the head and neck: the impact of smoking and P16-s
7. Salivary gland carcinoma in Denmark: a national update and follow-up on incidence, histology, and outcome
8. Socioeconomic position and the pre-diagnostic interval among patients diagnosed with head and neck squamous cell carcinoma - a population-based study from DAHANCA
9. A comparison of loco-regional relapse pattern in HPV positive vs negative oropharyngeal cancers following radiotherapy; relation to pretreatment FDG-PET and radiotherapy target volumes
10. Systemic bevacizumab for recurrent respiratory papillomatosis. A case series
11. HPV testing versus p16 immunohistochemistry in oropharyngeal squamous cell carcinoma: results from the DAHANCA 19 study.
12. Feasibility of Using Wearables for Home Monitoring during Radiotherapy for Head and Neck Cancer—Results from the OncoWatch 1.0 Study
13. Recommendations for a Patient Concerns Inventory specific to patients with head and neck cancer receiving palliative treatment
14. 675 TACTI-003: A randomized phase IIb study of eftilagimod alpha (soluble LAG-3 protein) and pembrolizumab as first-line treatment of patients with recurrent or metastatic head and neck squamous cell carcinoma
15. Association of Smoking, Comorbidity, Clinical Stage, and Treatment Intent With Socioeconomic Differences in Survival After Oropharyngeal Squamous Cell Carcinoma in Denmark
16. Paranasal Sinus and Nasal Cavity
17. Early non-cancer mortality risk prediction after curative-intent radiotherapy or chemoradiotherapy for head and neck squamous cell carcinoma
18. Treatment outcomes and survival following definitive (chemo)radiotherapy in HPV ‐positive oropharynx cancer: Large‐scale comparison of DAHANCA vs PMH cohorts
19. Treatment outcomes and survival following definitive (chemo) radiotherapy in HPV+ oropharynx cancer: Large scale comparison of two population-based cohorts
20. Pulmonary toxicity following IMRT after extrapleural pneumonectomy for malignant pleural mesothelioma
21. HER2 Positivity in Histological Subtypes of Salivary Gland Carcinoma: A Systematic Review and Meta-Analysis
22. Reply to Letter to the Editor regarding “Elective neck dissection and its extent in Salivary gland cancers: A Dilemma”
23. FDG-PET/CT identified distant metastases and synchronous cancer in squamous cell carcinoma of the head and neck: the impact of smoking and P16-s
24. Treatment outcomes and survival following definitive (chemo)radiotherapy in HPV‐positive oropharynx cancer: Large‐scale comparison of DAHANCA vs PMH cohorts.
25. Surgical treatment of the neck in patients with salivary gland carcinoma
26. Prognostic scoring models in parotid gland carcinoma
27. Randomized Phase II Study with Cetuximab in Combination with 5-FU and Cisplatin or Carboplatin Vs. Cetuximab in Combination with Paclitaxel and Carboplatin for Treatment of Patients with Relapsed or Metastatic Squamous Cell Carcinoma of the Head and Neck (CETMET Trial)
28. Paranasal Sinus and Nasal Cavity
29. PET/CT Based Dose Planning in Radiotherapy
30. Salivary gland carcinoma in Denmark: a national update and follow-up on incidence, histology, and outcome
31. A Non Platinum Regimen for the Treatment of Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck Region. Results From an Extended Phase II Study With Paclitaxel and Capecitabine
32. An Extended Hypofractionated Palliative Radiotherapy Regimen for Head and Neck Carcinomas
33. Associations between skin rash, treatment outcome, and single nucleotide polymorphisms in head and neck cancer patients receiving the EGFR-inhibitor zalutumumab: results from the DAHANCA 19 trial
34. Absorption of Bupivacaine after Administration of a Lozenge as Topical Treatment for Pain from Oral Mucositis
35. Incidence of and survival after glottic squamous cell carcinoma in Denmark from 1971 to 2011—A report from the Danish Head and Neck Cancer Group
36. The value of routine follow-up after treatment for head and neck cancer. A national DAHANCA study
37. The EXTREME regimen for recurrent/metastatic head and neck squamous cell carcinoma (R/M HNSCC): Treatment outcome in a single institution cohort
38. Absorption of Bupivacaine after Administration of a Lozenge as Topical Treatment for Pain from Oral Mucositis.
39. The value of routine follow-up after treatment for head and neck cancer. A National Survey from DAHANCA
40. Salivary gland carcinomas of the larynx: A national study in Denmark
41. The EXTREME regimen for recurrent/metastatic head and neck squamous cell carcinoma (R/M HNSCC): Treatment outcome in a single institution cohort.
42. Association of Smoking, Comorbidity, Clinical Stage, and Treatment Intent With Socioeconomic Differences in Survival After Oropharyngeal Squamous Cell Carcinoma in Denmark.
43. T1a glottic cancers may be removed by "cold steel" excision biopsies.
44. [Combined chemotherapy and radiotherapy in patients with nasopharyngeal cancer. A survey of a Cochrane review].
45. [Increased level of carcinoembryonal antigen is not primarily a marker for ovarian cancer].
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.